This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Ishir Bhan, MD, MPH, Massachusetts General Hospital Identifier:
First received: August 25, 2008
Last updated: March 15, 2016
Last verified: March 2016
Vitamin D deficiency (low levels of vitamin D in the blood) is a common problem. A recently discovered protein, called hCAP18, likely plays an important role in the immune system and may depend on adequate levels of vitamin D. It is not known what levels of vitamin D are needed to allow the body to make this protein. Nor is it known if giving vitamin D to people who are found to be deficient will help boost levels of hCAP18. This study aims to clarify the relationship between vitamin D levels and hCAP18.

Condition Intervention
Healthy Subjects Vitamin D Deficiency Drug: ergocalciferol

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Ishir Bhan, MD, MPH, Massachusetts General Hospital:

Primary Outcome Measures:
  • hCAP18 Levels [ Time Frame: Baseline ]
  • Baseline 25-OH Vitamin D Level [ Time Frame: Baseline ]

Enrollment: 99
Study Start Date: July 2007
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
Drug: ergocalciferol
Ergocalciferol 50,000 IU given every other day for 5 total doses
Other Name: Vitamin D
No Intervention: Vitamin D sufficient
Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-80

Exclusion Criteria:

  • Known active infectious disease or chronic inflammatory disorder
  • Hypercalcemia
  • Chronic kidney disease
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00742235

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Ishir Bhan, MD MPH Massachusetts General Hospital
  More Information

Responsible Party: Ishir Bhan, MD, MPH, Instructor in Medicine, Massachusetts General Hospital Identifier: NCT00742235     History of Changes
Other Study ID Numbers: 2008-P-0003000/1
Study First Received: August 25, 2008
Results First Received: June 5, 2013
Last Updated: March 15, 2016

Additional relevant MeSH terms:
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on August 16, 2017